YJU2

Across TCGA pan-cancer cohorts, YJU2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated YJU2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher YJU2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated YJU2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, UCEC, and LUAD are the cancer types where YJU2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.912	0.718	.001	35	view →
UCEC	OS	Quartile	II,III,IV	0.391	1.000	.010	20	view →
LUAD	DFS	Tertile	II,III,IV	0.845	0.194	.007	19	view →
HNSC	OS	Tertile	All	0.779	0.926	.020	14	view →
GBM	OS	Tertile	All	0.693	0.297	.001	4	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

YJU2–LSCC (OS)

Open the LSCC breakdown →